PTC Therapeutics | PTCT - Current Assets


PTC Therapeutics reported $2.62B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Cytokinetics USD 1.21B 369.02M Jun/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 12.53B 6.11B Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026
Xencor USD 523.21M 40.36M Jun/2026